- SIGA Technologies Inc SIGA provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.
- In recent weeks, the company initiated trials in the U.S., the U.K., and Congo to further assess the safety and efficacy of TPOXX in participants with monkeypox.
- These randomized clinical trials are now enrolling patients.
- Study of Tecovirimat for Human Monkeypox Virus (STOMP; A5418) is a U.S.-based clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). Study investigators aim to enroll more than 500 participants, including children.
- PLATINUM is a U.K.-based clinical trial commissioned and funded by the National Institute for Health Care and Research (NIHR), intending to recruit at least 500 participants.
- PALM 007 is a Congo-based clinical trial sponsored by NIAID and Institute National de Recherche Biomédicale (INRB). Study investigators aim to enroll more than 450 participants, including children weighing ≥3 kg and those who are pregnant or breastfeeding.
- In 2018, the FDA approved oral TPOXX for smallpox.
- SIGA disclosed that as of mid-September, it received approximately $76 million of international orders for oral TPOXX from twelve international customers.
- Price Action: SIGA shares are down 0.17% at $9.08 during the market session on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.